AKTX - Company ID 0001541157
Akari Therapeutics Plc trades as AKTX. This page tracks Akari Therapeutics Plc through 710 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Next research step
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| PRE 14A | - | 2026-05-22 |
| Major company event | 8-K | 2026-05-22 |
| RW | - | 2026-05-21 |
| Quarterly report | 10-Q | 2026-05-19 |
| NT 10-Q | - | 2026-05-18 |
| IPO registration | S-1 | 2026-05-08 |
| EFFECT | - | 2026-04-15 |
| POS AM | - | 2026-04-10 |
The largest companies sharing Akari Therapeutics Plc's SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Akari Therapeutics Plc reported a net loss of $17.30M.